Publications

Kodali PB, Pednekar MS, Gupta PC, Quah ACK, Fong G?, Bialous SA, Vijayaraghavan M. Cessation outcomes and healthcare provider advice to quit among tobacco users: A cross-sectional analysis of the 2018-2019 Tobacco Control Policy (TCP) India survey. Tobacco induced diseases. 2026. PMID: 41716892

Emamekhoo H, Riaz IB, Martin DB, Gabriel PE, Shah NJ, Bruckner L, Arafat W, Fu P, Freimuth RR, Liebovitz DM, Stillman RC, Stapp RT, Perkins RM, Sugalski J, Heinrichs T, Tevaarwerk AJ. Deriving wisdom from data: The value and continued rationale for structured data in the era of artificial intelligence-driven oncology care. Cancer. 2026. PMID: 41701629

Liu CH, Chen YL, Ai W, Ni HC, Lai MC. The impact of autism on the relations between social anxiety, camouflaging, and depression in Taiwanese adolescents. Child and adolescent psychiatry and mental health. 2026. PMID: 41689079

Zhu X, Alvarez EA, Umetsu SE, Chapman JS, Chen LM, Ueda S, Henderson S, Nguyen P, Calabrese S, Russell J, Aguilar J, Smith SA, Shah N, Feeney L, Van Ziffle J, Turski ML, Ko AH, Munster PN, Ashworth A, Collisson EA, Aggarwal RR. Efficacy of the ATR inhibitor ceralasertib in patients with ARID1A-deficient gynecologic and other solid tumor malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 41686845

Basu A, Umashankar S, Melisko M, Roy R, Yau C, Pusztai L, Chien AJ, Liu M, Han H, Soliman H, Isaacs C, Shatsky R, Stringer-Reasor E, Robinson P, Yeung K, Kalinsky K, Thomas A, Philip E, Musthafa M, Hirst G, Asare A, DeMichele A, Van't Veer L, Yee D, Hylton N, Olshen A, Perlmutter J, Cohen RN, Quandt Z, Esserman L, Hershman D, Rugo H, Nanda R. Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial. Research square. 2026. PMID: 41727611

Vieira Dos Santos J, Melnekoff DT, Aleman A, Mouhieddine TH, Montes de Oca R, Wang F, Rajeeve S, Bhalla S, Van Oekelen O, Upadhyaya B, Ghodke-Puranik Y, Leshchenko V, Kim-Schulze S, Rahman A, Afik S, Lewinsky H, Plaks V, Thibaud S, Cho HJ, Richter J, Rodriguez C, Sanchez L, Rossi A, Richard S, Chari A, Madduri D, Jagannath S, Parekh S, Laganà A. Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression. Blood advances. 2026. PMID: 41191534

Choucair A, Zdunek A, Liao M, Bodei L, Deandreis D, Das J, Barbe R, Bergsland E, Geyer S, Bidault F, Garcia G, Yeh R, Balleyguier C, Lassau N, Dercle L, Ammari S. Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management. Insights into imaging. 2026. PMID: 41661399

Manabe T, Bergo HC, Li Q, Wang TS, Severson P, Miller N, Lee C, Yay Donderici E, Zhang N, Wu W, Chou YT, Kerr DL, Allegakoen P, Grandinetti KB, Soroceanu L, Pelham RJ, Martin ES, Murphy EA, Khanna V, Neal JW, Chen CT, Kato S, Williams R, Bivona TG. Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies. Nature communications. 2026. PMID: 41654519

Spinner MA, Advani RH. Management of Classic Hodgkin Lymphoma in Pregnancy. Hematology/oncology clinics of North America. 2026. PMID: 41654459

Lopez CM, Suarez JF, Mendoza MA, Anderson AD, Lykon J, Li W, Morris MI, Natori Y, Raja M, Lekakis LJ, Beitinjaneh A, Jimenez A, Goodman M, Wang TP, Spiegel J, Holtzman NG, Pereira D, Green D, Komanduri KV, Camargo JF. Clinical Characteristics and Outcomes of Invasive Aspergillosis in Patients with Hematological Malignancies and Transplantation and Cellular Therapies in the Contemporary Era. Mycopathologia. 2026. PMID: 41642400

Srinagesh HK, Gupta VK, Zhang A, Grunwald MR, Connor MP, Kota VK, Boccucci J, Ulrickson ML, Pradeep R, Hill LC, Tsai SB, O'Connor TE, Sandhu KS, Advani AS, Reshef R, Gordillo CA, Luskin MR, Chen EC, Lin C, Cassaday RD, Kopmar NE, Majhail NS, Battiwalla M, Strickland SA, Lee CJ, Odstrcil Bobillo S, Hilal T, Park JH, Valtis YK, Faramand RG, Solh MM, Guzowski C, Vasu S, Leonard JT, Tan V, Wang ES, McCauley R, Sasine JP, Tang K, Miller K, Sutherland KC, Daunov M, Mohty R, Jamy O, Kumaran M, Hoeg RT, Dykes KC, Logan AC, Othman T, Stock WA, Schwartz MS, Byrd K, Yalniz FF, Bachanova V, Tracy SI, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole OO, Dholaria B, O'Dwyer KM, Moore J, Roloff GW, Frey NV, Aldoss I, Shah BD, Oliai C, Muffly LS. Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene. Blood. 2026. PMID: 41643192

Wilbur HC, Zhao LX, Nakazawa M, Kao C, Gordan JD, Gade TP, Cope L, Kagohara LT, Zabransky D, Ho WJ, Baretti M, Yarchoan M. Baseline and dynamic cytokines as biomarkers for immune checkpoint and anti-VEGF therapy in advanced hepatocellular carcinoma. ESMO gastrointestinal oncology. 2026. PMID: 41994022

Zeidner JF, Jain J, Welkie RL, Huang Y, Swords R, Traer E, Stein EM, Lin TL, Madanat YF, Collins RH, Baer MR, Duong VH, Blum W, Arellano ML, Stock WA, Odenike O, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran E, Handa S, Heerema NA, Chen TL, Martycz M, Stefanos M, Marcus S, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Mims AS, Byrd JC, Borate UM. Clinical Outcomes of Older Patients with NPM1-Mutated or KMT2A-Rearranged AML Before Menin Inhibitors: A Beat AML Report. Blood advances. 2026. PMID: 41632633

Balch CM, Liao N, Lam DSC, Weitzel JN, Xu RH, Attard G, Bunn PA, Eggermont AMM, He J, Kitagawa Y, Lim ST, Cazap E, Esquivel B, Fan X, Chow LWC, Liu ESF, Said HM, Niederhuber JE, Rubio IT, Zaghloul AS, Arrieta OG, Audisio RA, Beets GL, Coimbra FJF, Gallardo JE, Garber JE, Gronchi A, Heinemann V, Kurian AW, Mutebi M, Mori M, Olopade FI, Rutkowski P, Saleh M, Sanchez WM, Sawaya R, Thompson JF, Tumusiime G, Vallejos CS, Whiteman DC, Wu Y, Yawe KT, Zahrani NAA, Zoras O, Arun BK, Fabian CJ, Gershenwald JE, Gradishar WJ, He J, Kimberg VS, Lam RMK, Lee VHF, Lorusso D, Mok TSK, Perrier ND, Rugo HS, Ulrich C, Are C, Vignat J, Soerjomataram I. The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection. Ecancermedicalscience. 2026. PMID: 41877745

Han Y, Byun J, VanLith CJ, Cooley MA, Shaw VR, Hatia RI, Ahmed FY, Giama NH, Ali HM, Campbell NA, Hassan M, Andersen JB, Ankoma-Sey V, Banales JM, Bujanda L, Bathe OF, Bekaii-Saab TS, Borad MJ, Björkström NK, Chan CHF, Cleary SP, Cornillet M, Folseraas T, Galle PR, Genkinger JM, MacInnis RJ, Gores GJ, Goyal L, Houlston RS, Ilyas SI, Javle M, Johansen JS, Christensen TD, Kamath AS, Kelley RK, Khan SA, Kim RD, Kwee SA, Lamarca A, Lammert F, LaRusso NF, Lindsey S, Macias RIR, Malhi H, Patel TC, Permuth JB, Reeves HL, Rossi S, Sanchez W, Smoot RL, Swerdlow AJ, Tran Cao HS, Valle JW, Weinmann A, Weinmann-Menke J, Wong LL, Zhang X, Zimmer V, Zhu AX, Lazaridis KN, Juran BD, Jalal P, Knox JJ, Hutchinson A, Hicks B, Koshiol JE, Chanock SJ, Hassan MM, Amos CI, McGlynn KA, Roberts LR. Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses. Hepatology (Baltimore, Md.). 2026. PMID: 41627892

Aggarwal R, Bhatt DL, Miller M, Ballantyne CM, Brinton EA, Jacobson TA, Ketchum SB, Tardif JC, Budoff MJ, Figtree GA, Steg PG, REDUCE-IT Investigators. Cardiovascular outcomes with icosapent ethyl by burden of standard modifiable cardiovascular risk factors in REDUCE-IT. American journal of preventive cardiology. 2026. PMID: 42006413

Advani RH, Kelsey CR, Armand P, Bello CM, Benitez CM, Bond D, Chen W, Cherian S, Czader M, Dabaja B, Daly ME, Frosch Z, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Hoppe RT, Isufi I, Johnston PB, Kelly K, Kenkre VP, Kline J, Lynch RC, McConathy J, Morgan D, Niu A, Paul S, Rabinovitch R, Salavati A, Sano D, Shah H, Spinner M, Svoboda J, Winter JN, Yahalom J, Yang JC, Montgomery S, Stehman K. Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41671432

Ma S, Spinner MA. Optimizing the Role of Checkpoint Inhibitors in the Management of Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41698326

O'Reilly EM, Cabanski CR, Lyman JP, Wainberg ZA, Fisher GA, Wolff RA, Ko AH, O'Hara MH, Spencer CN, Yu JX, Da Silva DM, Padrón LJ, Arnott J, Fairchild J, Moore JS, Peng B, Hoos WA, O'Donnell-Tormey J, Boffo S, Dugan U, Kimmelman AC, Amaravadi RK, Vonderheide RH. Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. Journal for immunotherapy of cancer. 2026. PMID: 41617393

Jhaveri KL, Iyengar NM, Turner NC, Rugo HS, O'Shaughnessy J, Barrios CH, Curigliano G, André F, Im SA, Goncalves MD, Lacouture ME, Fasching PA, Leung R. Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer. ESMO open. 2026. PMID: 41604817